|
Sub-category:
Quality-of-Life Management
Category:
Patient Care
Meeting:
2008 ASCO Annual Meeting
Abstract No:
9515
Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 9515)
Author(s):
A. D. TAN, P. J. Novotny, J. S. Kaur, J. C. Buckner, P. L. Schaefer, P. J. Stella, J. P. Kuebler, J. A. Sloan
Abstract:
Background: The significance of baseline QOL as a prognostic factor for survival in oncology clinical trials has been suggested in individual trials. We performed a patient-level meta-analysis of 24 NCCTG and MC oncology clinical trials of the effect of baseline QOL on OS. Methods: 3,704 patients participating in 24 oncology clinical trials provided data at baseline on overall QOL on a 0-100 point scale. OS (whole study group and per study) was tested for association with high vs low QOL (split at median >83 baseline QOL score), and clinically deficient (CD-QOL, score 0-50, n=540) vs not clinically deficient (nCD-QOL, score 51-100, n=3164) QOL. Cox proportional hazards models adjusted for the effects of performance score, race (minority vs. non-minority), site, age and gender. Results: Baseline QOL was a strong predictor of OS for the whole study group (low vs high QOL: 12.3 mos vs 18.4 mos, p<0.0001; CD-QOL vs nCD-QOL: 9.3 mos vs 16.8 mos, p=0.0001). The effect sizes were consistent across different disease sites (GI, GU, lung, breast and brain). Multivariate models indicated that even after controlling for the aforementioned covariates, including performance status, baseline QOL remained a strong prognostic factor (p<0.00001). Conclusions: Baseline QOL is a strong and independent prognostic factor for OS over and above PS in a wide variety of oncology patient populations and should thus be considered for routine inclusion as a stratification factor for all future randomized oncology treatment trials.
Abstract Disclosures
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
| |
1. A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials.
Meeting:
2008 ASCO Annual Meeting
Presenter:
Jeff A Sloan, PhD
Session:
Patient and Survivor Care
(Oral Presentation)
|
Other Abstracts in this Sub-Category:
Abstracts by A. D. TAN :
Presentations by A. D. TAN :
Educational Book Manuscripts by A. D. TAN :
|
